Researchers at the University of Calgary are testing high-dose vitamin B3 (niacin) as an add-on to standard glioblastoma treatment. Glioblastoma is an aggressive brain cancer that suppresses the immune system, preventing it from attacking tumor cells. Early results from a combined Phase I/II trial are encouraging: 82% of patients remained progression-free six months after diagnosis. The theory is that niacin can rejuvenate immune cells that the tumor has suppressed, restoring their ability to target and destroy cancer cells. The approach originated in mouse studies showing extended survival with niacin treatment. Researchers are using a controlled-release form of niacin alongside standard chemotherapy and radiotherapy. While the results are promising, the trial is small and larger studies are needed before any firm conclusions can be drawn about effectiveness and safety.
